Cholestyramine alleviates bone and muscle loss in irritable bowel syndrome via regulating bile acid metabolism
Cell Proliferation · 2024-08 · 57 (8)
DOI: 10.1111/cpr.13638 ↗At a glance
Journal article in Cell Proliferation, published online on 2024-03-25. Written by Ming Chen and 17 co-authors. Institution: Senior Department of Orthopedics, The Fourth Medical Center of Chinese PLA General Hospital, Beijing, China. Major MEDLINE topics: Irritable Bowel Syndrome, Cholestyramine Resin, Bile Acids and Salts, Gastrointestinal Microbiome. Cited 11 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: National High Level Hospital Clinical Research Funding, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (original language)
Irritable bowel syndrome (IBS) is a widespread gastrointestinal disorder known for its multifaceted pathogenesis and varied extraintestinal manifestations, yet its implications for bone and muscle health are underexplored. Recent studies suggest a link between IBS and musculoskeletal disorders, but a comprehensive understanding remains elusive, especially concerning the role of bile acids (BAs) in this context. This study aimed to elucidate the potential contribution of IBS to bone and muscle deterioration via alterations in gut microbiota and BA profiles, hypothesizing that cholestyramine could counteract these adverse effects. We employed a mouse model to characterize IBS and analysed its impact on bone and muscle health. Our results revealed that IBS promotes bone and muscle loss, accompanied by microbial dysbiosis and elevated BAs. Administering cholestyramine significantly mitigated these effects, highlighting its therapeutic potential. This research not only confirms the critical role of BAs and gut microbiota in IBS‐associated bone and muscle loss but also demonstrates the efficacy of cholestyramine in ameliorating these conditions, thereby contributing significantly to the field's understanding and offering a promising avenue for treatment.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Senior Department of Orthopedics, The Fourth Medical Center of Chinese PLA General Hospital, Beijing, China.
- National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, Beijing, China.
- Department of Clinical Nutrition, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- Department of Orthopedic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
ORCID profiles: Kang Yu, Peifu Tang
Funding
- National High Level Hospital Clinical Research Funding
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Cite
APA
Chen, M., Wei, W., Li, Y., Ge, S., Shen, J., Guo, J., Zhang, Y., Huang, X., Sun, X., Cheng, D., Zheng, H., Chang, F., Chen, J., Liu, J., Zhang, Q., Zhou, T., Yu, K., & Tang, P. (2024). Cholestyramine alleviates bone and muscle loss in irritable bowel syndrome via regulating bile acid metabolism. Cell Proliferation, 57(8). https://doi.org/10.1111/cpr.13638
Vancouver
Chen M, Wei W, Li Y, Ge S, Shen J, Guo J, et al. Cholestyramine alleviates bone and muscle loss in irritable bowel syndrome via regulating bile acid metabolism. Cell Proliferation. 2024;57(8). doi:10.1111/cpr.13638
BibTeX
@article{Chen2024,
author = {Chen, Ming and Wei, Wei and Li, Yi and Ge, Siliang and Shen, Junmin and Guo, Jiayu and Zhang, Yu and Huang, Xiang and Sun, Xinyu and Cheng, Dongliang and Zheng, Huayong and Chang, Feifan and Chen, Junyu and Liu, Jiang and Zhang, Qinxiang and Zhou, Tianjunke and Yu, Kang and Tang, Peifu},
title = {Cholestyramine alleviates bone and muscle loss in irritable bowel syndrome via regulating bile acid metabolism},
journal = {Cell Proliferation},
year = {2024},
volume = {57},
number = {8},
doi = {10.1111/cpr.13638}
}
EUVIMED